Last $53.75 USD
Change Today -0.01 / -0.02%
Volume 299.8K
As of 8:10 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

cyberonics inc (CYBX) Snapshot

Open
$53.96
Previous Close
$53.76
Day High
$54.23
Day Low
$53.53
52 Week High
02/14/14 - $73.52
52 Week Low
11/20/14 - $48.19
Market Cap
1.4B
Average Volume 10 Days
637.0K
EPS TTM
$2.37
Shares Outstanding
26.3M
EX-Date
--
P/E TM
22.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for CYBERONICS INC (CYBX)

cyberonics inc (CYBX) Related Bloomberg News

View More Bloomberg News

cyberonics inc (CYBX) Related Businessweek News

No Related Businessweek News Found

cyberonics inc (CYBX) Details

Cyberonics, Inc., together with its subsidiaries, designs, develops, markets, and sells implantable medical devices to hospitals and ambulatory surgery centers. The company offers vagus nerve stimulation (VNS) therapy system that uses pulsed electrical signals applied to the vagus nerve for the treatment of refractory epilepsy and treatment-resistant depression. It is also engaged in investigating the use of VNS and other neuromodulation therapy for other indications, including chronic heart failure, and developing non-implantable device solutions for the management of epilepsy. The company sells its products directly, as well as through independent distributors in Europe, Canada, Mexico, Australia, parts of Central and South America, the Middle East, China, Japan, and other parts of Asia. Cyberonics, Inc. was founded in 1987 and is headquartered in Houston, Texas.

639 Employees
Last Reported Date: 06/16/14
Founded in 1987

cyberonics inc (CYBX) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $613.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $334.1K
Chief Operating Officer and Senior Vice Presi...
Total Annual Compensation: $186.6K
Chief Administrative Officer, Senior Vice Pre...
Total Annual Compensation: $318.1K
Senior Vice President of Research & Developme...
Total Annual Compensation: $307.3K
Compensation as of Fiscal Year 2014.

cyberonics inc (CYBX) Key Developments

Cyberonics Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-08-2014 08:00 AM

Cyberonics Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-08-2014 08:00 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Rohan J. Hoare, Chief Operating Officer and Senior Vice President.

Cyberonics Inc. Announces Results from the ANTHEM-HF Clinical Study

Cyberonics Inc. announced results from the ANTHEM-HF clinical study. Results of the study show Autonomic Regulation Therapy (ART) in patients with moderate to severe chronic heart failure and impaired heart function is safe, improves the heart's ability to pump blood, and reduces symptoms associated with chronic heart failure. More than six million people in Europe have chronic heart failure, a syndrome characterized by the heart's inability to pump sufficient blood to meet the metabolic demands of the body. Results from the ANTHEM-HF clinical study were presented during a Hot Line Session at the European Society of Cardiology Congress and showed that heart failure (HF) patients on stable pharmacological therapy and treated with ART via vagus nerve stimulation experienced a clinically significant: -- improvement in heart pump function; average left ventricular ejection fraction increased from 32% at baseline to 37% after 6 months of ART; -- reduction in heart failure symptom burden; NYHA class improved in 77% of patients; -- improvement in quality of life (assessed by Minnesota Living with HF Questionnaire); -- increase in functional capacity (assessed by Six-minute walk distance); and -- improvement in autonomic regulation of heart rate.

Cyberonics Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended July 25, 2014; Reaffirms Earnings Guidance for Fiscal 2015

Cyberonics Inc. announced unaudited consolidated earnings results for the first quarter ended July 25, 2014. For the quarter, the company reported net sales of $72,003,966 compared to $68,872,357 for the same period a year ago. Income from operations was $22,003,214 compared to $13,604,041 for the same period a year ago. Income before income tax was $22,212,335 compared to $13,516,765 for the same period a year ago. Net income was $13,518,822 compared to $8,673,926 for the same period a year ago. Diluted income per share was $0.50 compared to $0.31 for the same period a year ago. Net cash provided by operating activities was $18,097,791 compared to $9,487,656 for the same period a year ago. Intangible asset purchases were nil compared to $1,250,000 for the same period a year ago. Purchases of property, plant and equipment were $1,815,500 compared to $5,533,847 for the same period a year ago. Adjusted non-GAAP income from operations was $22,003,214 compared to $19,579,019 for the same period a year ago. Adjusted non-GAAP net income was $14,323,928 compared to $12,529,132 for the same period a year ago. Adjusted non-GAAP diluted income per share was $0.53 compared to $0.45 for the same period a year ago. Adjusted EBITDA was $27,076,271 compared to $24,089,519 for the same period a year ago. The company reaffirmed earnings guidance for fiscal 2015. For the period, net sales are expected to be in the range of $300 million to $307 million. Gross profit margin is expected to be between 90.0% and 91.0%. Income from operations is expected to be in the range of $96 million to $99 million. The company anticipates an adjusted effective tax rate of approximately 35% for fiscal 2015, which assumes the renewal of the R & D tax credit. Adjusted net income for fiscal 2015 is expected to be in the range of $62 million to $64 million. Adjusted diluted earnings per share will be in the range of $2.33 to $2.39.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYBX:US $53.75 USD -0.01

CYBX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Exactech Inc $22.59 USD +0.43
ICU Medical Inc $84.50 USD +0.87
Thoratec Corp $31.10 USD -0.17
Tornier NV $27.34 USD +0.46
Wright Medical Group Inc $29.59 USD +0.37
View Industry Companies
 

Industry Analysis

CYBX

Industry Average

Valuation CYBX Industry Range
Price/Earnings 23.0x
Price/Sales 5.0x
Price/Book 5.3x
Price/Cash Flow 22.4x
TEV/Sales 4.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYBERONICS INC, please visit www.cyberonics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.